Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma
Spread of lymph node metastasis and adjuvant therapy for distal cholangiocarcinoma
复制标题
远端胆管癌的淋巴结转移及辅助治疗
DOI:
10.1007/s10147-022-02175-z
复制
发表时间:
2022
影响因子:
3.3
通讯作者:
Ohtsuka Takao
中科院分区:
文献类型:
--
作者:
Kurahara Hiroshi;Mataki Yuko;Idichi Tetsuya;Kawasaki Yota;Mori Shinichiro;Sasaki Ken;Arigami Takaaki;Nakajo Akihiro;Fukukura Yoshihiko;Higashi Michiyo;Ohtsuka Takao
BackgroundLymphatic metastasis is a major route of metastasis in distal cholangiocarcinoma (DCC). The present study aimed to elucidate the pattern of lymph node (LN) metastasis and the effectiveness of LN dissection and postoperative adjuvant chemotherapy in patients with DCC.MethodsPatients who underwent surgical resection with curative intent for DCC were enrolled. The nomenclature of the LN stations was defined according to the Japanese Society of Hepato-Biliary-Pancreatic Surgery guidelines. Effectiveness of LN dissection of each station was calculated using frequency of LN metastasis to the station and 5-year survival rate of patients with LN metastasis to that station.ResultsOf the 105 patients included in the study, 46 (43.8%) had LN metastasis, and 43 (41.0%) underwent postoperative adjuvant therapy. LN metastasis, serum carbohydrate antigen (CA) 19–9 level > 37 U/mL, and positive bile duct margin were independent risk factors for shorter overall survival (OS). The most common metastatic LN station at surgery was No. 13 (32.7%), followed by No. 12 (19.2%), No. 17 (9.6%), and No. 8 (6.6%). There was no effectiveness of LN dissection of the station No. 8, 14, and 16. Adjuvant chemotherapy was significantly associated with longer OS in patients with LN metastasis but not in those with positive ductal margins or serum CA 19–9 level > 37 U/mL.ConclusionsPostoperative adjuvant chemotherapy was associated with a better prognosis in patients with DCC and LN metastasis. However, a more effective therapeutic strategy is required to improve the prognosis of patients with other negative prognostic factors.
登录
查看更多内容
DOI:
10.1093/annonc/mdy282.146
发表时间:
2018
期刊:
Annals of oncology : official journal of the European Society for Medical Oncology
影响因子:
--
作者:
S. Yadav;H. Xie;I. Riaz;Pankaj Sharma;A. Mahipal;R. McWilliams
通讯作者:
R. McWilliams
DOI:
--
发表时间:
--
期刊:
影响因子:
--
作者:
通讯作者:
--
影响因子:
3.7
作者:
Murakami, Yoshiaki;Uemura, Kenichiro;Sueda, Taijiro
通讯作者:
Sueda, Taijiro
影响因子:
9.6
作者:
Ebata, T.;Hirano, S.;Nagino, M.
通讯作者:
Nagino, M.
影响因子:
9.6
作者:
Murakami, Y.;Satoi, S.;Honda, G.
通讯作者:
Honda, G.